DigestRedComo funciona
Red
/
Empresas
To
No verificado

Tolerance Bio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMercado laboralSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
28/09/2026
Mercado laboral
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Tolerance Bio Licenses Clinical-Stage Anti-IL-33 Monoclonal Antibody from Tanabe Pharma to Expand Thymus-Focused Clinical Pipeline
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0
19/08/2026
Mercado laboral
Industria
Oncología
VIH, SIDA y enfermedades autoinmunes
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa from NeoImmuneTech to Advance Programs Targeting Thymic Function and Immune Resilience
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0
27/10/2025
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Industria
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0
08/09/2025
Biotecnología
Farmacéutica
Salud
Mercado laboral
Industria
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0
19/12/2024
Mercado laboral
Biotecnología
Farmacéutica
Salud
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0
15/10/2024
Ciencia
VIH, SIDA y enfermedades autoinmunes
Finanzas
Asociaciones/Profesionales
Biología
Biotecnología
Sanidad
Farmacéutica
Salud
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
Fuente
Tolerance Bio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0